Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

Sidoti May 2024 Virtual Investor Conference
Format: Company Presentation
Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
Location: Virtual

The Citizens JMP Life Sciences Conference
Format: Fireside Chat
Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
Location: New York Hilton Midtown

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on X , (formerly known as Twitter ) , and Instagram .

Investor Contacts:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
332-213-1956

Media Contact:
Janine Bogris
Inizio Evoke Comms
Janine.bogris@inizioevoke.com
201-245-6838


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
Stallion Uranium Commencing Ground Electromagnetic Survey on the Coyote Corridor

Stallion Uranium Commencing Ground Electromagnetic Survey on the Coyote Corridor

Stallion Uranium Corp. (the " Company " or " Stallion " ) (TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0) pleased to announce that it will commence a high-resolution ground Time Domain Electromagnetic (TDEM) survey on November 1, 2025, on its Coyote Target, part of the Moonlite Project in the Athabasca... Keep Reading...
Standard Uranium Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project

Standard Uranium Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce preliminary results from its 2025 exploration programs the Corvo Uranium Project ("Corvo", or the "Project"), currently under a three-year earn-in option agreement... Keep Reading...
Stallion Uranium Appoints Peter Dembicki to Board of Directors, Initiates Haystack Intelligent Targeting Study

Stallion Uranium Appoints Peter Dembicki to Board of Directors, Initiates Haystack Intelligent Targeting Study

Stallion Uranium Corp. (the " Company " or " Stallion ") ( TSX-V: STUD ; OTCQB: STLNF ; FSE: B76 ) is pleased to announce the appointment of Mr. Peter Dembicki to its Board of Directors, bringing significant capital markets and governance expertise to the Company. In tandem with this strategic... Keep Reading...
Stallion Uranium Announces Grant of Options

Stallion Uranium Announces Grant of Options

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that under the Company's stock option plan dated October 8, 2024 (the " Plan "), the... Keep Reading...
Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

Stallion Uranium Completes Second and Final Tranche of Oversubscribed $15,000,000 Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Stallion Uranium Corp. (the " Company " or " Stallion " ) ( TSX-V: STUD ; OTCQB: STLNF ; FSE: FE0 ) is pleased to announce that it has closed a second and final tranche of its previously announced non-brokered... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News